Biocon raises ₹4,500 crore through QIP
Biocon said it completed its Qualified Institutions Placement (QIP) and raised ₹4,500 crore through the issuance of 13,63,63,635 equity shares of face value ₹5 each to eligible qualified institutional buyers at the issue price of ₹330 per equity share (including a premium of ₹325 per equity share).
The QIP, which opened on June 16 and closed on June 19, witnessed robust investor interest from a diverse group of domestic and international investors, underscoring strong confidence in Biocon's growth prospects, said the company on Friday.
Siddharth Mittal, CEO and Managing Director, Biocon Limited, said, 'The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide.'
According to the company, this fundraise, the first equity fundraise done by Biocon since its IPO in 2004, demonstrates the company's access to a diversified equity pool of capital.
The final order book was well diversified in terms of investor type across domestic mutual funds, insurance companies and foreign institutional investors. Some of the leading names who participated in the issue included SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life Insurance, Nippon India Mutual Fund, Mirae Asset Mutual Fund, Aditya Birla Mutual Fund, Franklin Templeton, SBI General Insurance, Government Pension Fund Global and Blackrock, the biotech firm further said.
The proceeds from the QIP would be utilised towards purchase of outstanding optionally convertible debentures issued by Biocon Subsidiary, Biocon Biologics Limited, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2. Also, proceeds would be used for repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments issued and/or borrowings availed by the company, and/or meeting other financial commitments of the company; and for general corporate purposes, as per the company.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Biocon closes ₹4,500 crore QIP to boost innovation, expand global access
Biocon Ltd announced on Friday that it has successfully raised ₹4,500 crore through a qualified institutions placement (QIP), marking its first equity fundraising since its initial public offering in 2004. In a regulatory filing, the company stated it had issued over 136.3 million equity shares, each with a face value of ₹5, to eligible institutional investors. The shares were priced at ₹330 per unit, which includes a premium of ₹325. The QIP was open from June 16 to 19, 2025, and received strong interest from both Indian and global investors. Biocon said this response reflects growing confidence in the company's long-term strategic vision. Capital to support innovation and access to affordable healthcare 'The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution,' said Siddharth Mittal, CEO and Managing Director of Biocon Ltd. 'This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide,' Mittal added. Proceeds allocated for strategic and financial needs Biocon stated that part of the capital raised will be used to purchase outstanding optionally convertible debentures of its subsidiary, Biocon Biologics Limited, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme - 2. Additionally, the funds will be used to repay, pre-pay, or redeem certain borrowings and financial instruments, and meet other financial requirements, including general corporate expenses.
The Hindu
4 hours ago
- The Hindu
Biocon raises ₹4,500 crore through QIP
Biocon said it completed its Qualified Institutions Placement (QIP) and raised ₹4,500 crore through the issuance of 13,63,63,635 equity shares of face value ₹5 each to eligible qualified institutional buyers at the issue price of ₹330 per equity share (including a premium of ₹325 per equity share). The QIP, which opened on June 16 and closed on June 19, witnessed robust investor interest from a diverse group of domestic and international investors, underscoring strong confidence in Biocon's growth prospects, said the company on Friday. Siddharth Mittal, CEO and Managing Director, Biocon Limited, said, 'The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide.' According to the company, this fundraise, the first equity fundraise done by Biocon since its IPO in 2004, demonstrates the company's access to a diversified equity pool of capital. The final order book was well diversified in terms of investor type across domestic mutual funds, insurance companies and foreign institutional investors. Some of the leading names who participated in the issue included SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life Insurance, Nippon India Mutual Fund, Mirae Asset Mutual Fund, Aditya Birla Mutual Fund, Franklin Templeton, SBI General Insurance, Government Pension Fund Global and Blackrock, the biotech firm further said. The proceeds from the QIP would be utilised towards purchase of outstanding optionally convertible debentures issued by Biocon Subsidiary, Biocon Biologics Limited, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2. Also, proceeds would be used for repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments issued and/or borrowings availed by the company, and/or meeting other financial commitments of the company; and for general corporate purposes, as per the company.
India Today
17 hours ago
- India Today
Stocks to watch today: Oswal Pumps, Biocon, United Spirits, Sai Life Sciences
Stock markets remained volatile and ended flat on Wednesday, as investors stayed cautious due to weak global cues and growing tension in the Middle East. On Friday, a mix of company updates and investor actions may influence specific stocks on Dalal a major player in the biopharmaceutical industry, has closed its qualified institutional placement (QIP) issue. The company finalised the allotment of 13.63 crore shares, raising Rs 4,500 crore. These shares were allotted at Rs 330 each. Notable investors in the QIP include ICICI Prudential Mutual Fund, SBI Mutual Fund, HDFC Life Insurance, Nippon Life India, Mirae Asset, and Franklin SpiritsUnited Spirits has announced that it will buy 37,683 equity shares of Nao Spirits & Beverages in two parts from existing shareholders. The cost of this acquisition is Rs 53.80 crore. In addition to this, United Spirits will subscribe to 31,820 new equity shares and 27,577 compulsorily convertible preference shares (CCPS) for Rs 56 crore. Once the first part of this transaction is completed, United Spirits will own 97.07% of Nao Spirits, making it a Life SciencesSai Life Sciences may see movement today as TPG Asia VII SF Pte is expected to sell a 6% stake in the company. This translates to around 1.25 crore shares, according to a CNBC-TV18 report. The deal is likely to be worth about USD 102 million, with a base price set at Rs 710 per share. The block deal could draw attention from institutional investors and Technology IndiaKaynes Technology has launched its QIP on June 19. The floor price has been fixed at Rs 5,625.75 per share. According to sources quoted by CNBC-TV18, the company aims to raise up to Rs 1,600 crore through this offer. The QIP is likely to help the company with expansion plans or strengthen its IndiaShares of Nestle India could be in focus after the company announced that its Board of Directors will meet on June 26. They will consider a proposal to issue bonus shares. Investors will watch this development closely, as bonus shares usually lead to positive market OneDevender Kumar, the Chief Revenue Officer of Direct Business at Angel One, has resigned. His last working day will be September 30. Management changes at senior levels often affect investor confidence and may have a short-term impact on stock shares may be under pressure after Goldman Sachs sold more than 1.77 lakh shares through a block deal. The total deal size was Rs 48 crore, with the shares sold at a price of Rs 2,700.6 PumpsThough the listing is expected on June 20, market participants will watch Oswal Pumps closely. Its IPO received strong demand across all investor categories, and the grey market premium has hinted at a positive listing. Final price movement on debut will give an indication of investor confidence in the these updates, markets may see stock-specific action even as broader cues remain uncertain. advertisement
